Nachrichten zur Mirati Therapeutics Inc. Aktie

Form 8-K Mirati Therapeutics, For: May 24

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Form 8-K Mirati Therapeutics, For: May 11

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Mirati (MRTX) Q1 Earnings & Revenues Beat Estimates, Stock Up

Mirati (MRTX) reports better-than-expected first-quarter results, wherein earnings and revenues beat estimates. The stock climbs 2% on Tuesday. Pipeline development…

Form 10-Q Mirati Therapeutics, For: Mar 31

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates

SAN DIEGO, May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial…

Mirati Therapeutics® to Report First Quarter 2023 Financial Results and Recent Corporate Updates on May 9, 2023

SAN DIEGO, April 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, will announce financial…

Strength Seen in Mirati (MRTX): Can Its 13.5% Jump Turn into More Strength?

Mirati (MRTX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate…

Mirati (MRTX) Reports Q4 Loss, Misses Revenue Estimates

Mirati (MRTX) delivered earnings and revenue surprises of 6.15% and 75.17%, respectively, for the quarter ended December 2022. Do the…

Mirati Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates

SAN DIEGO, Feb. 28, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial stage biotechnology company, today announced financial…

Mirati Therapeutics to Participate at the 43rd Annual Cowen Health Care Conference

SAN DIEGO, Feb. 21, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate at the…

Mirati Therapeutics to Report Fourth Quarter and Full Year Financial Results for 2022 and Recent Corporate Updates on February 28, 2023

SAN DIEGO, Feb. 14, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will announce financial results…

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN DIEGO, Feb. 3, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that…

Mirati Therapeutics to Participate in Two Upcoming Healthcare Conferences

SAN DIEGO, Feb. 1, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a targeted oncology company, will participate in two…

Mirati (MRTX) KRAS Candidate MRTX1133 to Enter Clinical Stage

Mirati Therapeutics (MRTX) announces IND clearance for oral KRASG12D selective inhibitor, MRTX1133, by the FDA. It is set to initiate…

Insiderhandel: Aufsichtsrat verkauft Aktien von Mirati Ther im Wert von 113.704$

Cherrington, Julie M. - Aufsichtsrat - Tag der Transaktion: 2023-01-18...…

Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133

IND demonstrates Miratis leadership in KRAS, representing the Companys third KRAS or KRAS-signaling program to enter clinical development SAN DIEGO,…

Insiderhandel: Chief Executive Officer verkauft Aktien von Mirati Ther im Wert von 134.715$

Meek, David D. - Vorstand - Tag der Transaktion: 2023-01-17...…

Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Mirati Ther im Wert von 66.366$

Hickey, Benjamin - Vorstand - Tag der Transaktion: 2023-01-17...…

Insiderhandel: EVP, Chief Scientific Officer verkauft Aktien von Mirati Ther im Wert von 95.142$

Christensen, Jamie - Vorstand - Tag der Transaktion: 2023-01-17...…

Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Mirati Ther im Wert von 94.733$

Hickey, Benjamin - Vorstand - Tag der Transaktion: 2023-01-09...…

Form 8-K Mirati Therapeutics, For: Jan 09

Um den gesamten Artikel unter streetinsider.com zu lesen, klicken Sie bitte auf die Überschrift...…

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN DIEGO, Jan. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that…

Kaskela Law LLC Announces Investigation of Mirati Therapeutics, Inc. (MRTX) and Encourages Long-Term MRTX Investors to Contact the Firm

Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2023) - Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ:…

Insiderhandel: President,Founder,Head of R&D verkauft Aktien von Mirati Ther im Wert von 169.997$

Baum, Charles M. - Vorstand - Tag der Transaktion: 2023-01-04...…

Insiderhandel: EVP, Chief Scientific Officer verkauft Aktien von Mirati Ther im Wert von 90.823$

Christensen, Jamie - Vorstand - Tag der Transaktion: 2023-01-04...…

Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

SAN DIEGO, Dec. 22, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that…

Mirati Therapeutics gets a Breakthrough designation for its colorectal cancer drug

Shares of Mirati Therapeutics Inc. jumped 6.0% in premarket trading on Thursday after the company said the Food and…

Pre-market Movers: ORIC Pharmaceuticals, Ocuphire Pharma, Transportadora de Gas del Sur, Mirati Therapeutics, Par Pacific

BUENOS AIRES (dpa-AFX) - The following are some of the stocks making big moves in Thursdays pre-market trading (as of…

Insiderhandel: EVP, Chief Commercial Officer verkauft Aktien von Mirati Ther im Wert von 131.266$

Hickey, Benjamin - Vorstand - Tag der Transaktion: 2022-12-21...…

Insiderhandel: President,Founder,Head of R&D verkauft Aktien von Mirati Ther im Wert von 367.469$

Baum, Charles M. - Vorstand - Tag der Transaktion: 2022-12-21...…

Insiderhandel: Chief Executive Officer verkauft Aktien von Mirati Ther im Wert von 186.552$

Meek, David D. - Vorstand - Tag der Transaktion: 2022-12-21...…

Mirati up 4% as Krazati granted Breakthough Therapy designation for colorectal cancer

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Mirati draws Hold rating at Needham despite recent selloff

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...…

Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

SAN DIEGO, Dec. 13, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that…

Miratis lung cancer drug gets an accelerated approval

Shares of Mirati Therapeutics Inc. were up about 3% in premarket trading on Tuesday, the day after the company…

Mirati (MRTX) Up on FDA Nod to Adagrasib for KRAS Mutated NSCLC

The accelerated approval of Mirati Therapeutics (MRTX) Krazati is based on ORR and DOR data from the phase II registration-enabling…

Therapie für nicht-kleinzelliges Lungenkarzinom: QIAGEN erhält FDA-Zulassung für Begleitdiagnostikum zu KRAZATI von Mirati Therapeutics

GERMANTOWN, Md. & HILDEN, Deutschland--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat von der US-amerikanischen Arzneimittelzulassungsbehörde FDA die Zulassung…

dpa-AFX ProFeed